# 2025-09988: A Little-Known Amphetamine Could Soon Join Schedule I 2025-09988, Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2025-06-03, effective If finalized, the rule would apply as of the effective date of a final scheduling action; comments and hearing requests must be submitted on or before July 3, 2025.; PRIA reads it as touching household money (as of 2026-10-27). - Canonical: https://policyrisk.com/federal-register/2025-09988 - As of: 2026-10-27 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2025-09988 - Title: Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I - Type: Proposed Rule - Agencies: Justice Department; Drug Enforcement Administration - Citation: 90 FR 23477 - Published: 2025-06-03 - Effective: If finalized, the rule would apply as of the effective date of a final scheduling action; comments and hearing requests must be submitted on or before July 3, 2025. - Comments close: not stated - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-10-27 ## In one line A Little-Known Amphetamine Could Soon Join Schedule I ## Summary The DEA wants to put 4-fluoroamphetamine (4-FA) into Schedule I, meaning it’s considered very risky and illegal to handle without strict rules. This affects anyone who makes, sells, studies, or possesses 4-FA, bringing serious legal consequences. You’ve got until July 3, 2025, to share your thoughts or ask for a hearing before this rule might become official. ## Abstract The Drug Enforcement Administration proposes placing the substance 4-fluoroamphetamine (4-FA; 1-(4-fluorophenyl)propan-2-amine), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4-fluoroamphetamine. ## Effects PRIA read - 4‑FA Proposed Placement in Schedule I: cost, medium. The DEA proposes to place 4‑fluoroamphetamine (4‑FA), including its salts, isomers, and salts of isomers, into Schedule I of the Controlled Substances Act. If finalized, 4‑FA would be treated as a Schedule I drug, meaning handling it (manufacture, distribution, research, import/export, or possessio… - Registration and Compliance Required to Handle 4‑FA: cost, medium. If the rule is finalized, anyone who wants to handle 4‑FA (manufacture, distribute, import, export, research, instructional use, chemical analysis, or possess it) must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and follow rules in 21 CFR parts 1301–1312. Registered handlers would… - Immediate Disposal or Transfer Requirement for Unregistered Holders: cost, medium. People or entities that currently possess 4‑FA but do not have DEA registration would need to apply for registration and may not continue to handle 4‑FA as of the effective date of a final scheduling action unless the DEA has approved their registration. Those who do not obtain registration must su… - Unauthorized Handling Subject to Sanctions: cost, medium. Any activity involving 4‑FA that is not authorized by the Controlled Substances Act or DEA regulations would be unlawful and may subject the person to administrative, civil, and/or criminal sanctions. This applies as of the effective date of a final scheduling action. - DEA Certifies Limited Small‑Entity Economic Impact: benefit, low. DEA reviewed the rule under the Regulatory Flexibility Act and certifies that placing 4‑FA in Schedule I is not expected to have a significant economic impact on a substantial number of small entities. The agency notes no evidence of significant diversion from legitimate suppliers and that 4‑FA is… ## Related documents - [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09 - [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20 - [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24 - [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19 - [2026-21725](https://policyrisk.com/federal-register/2026-21725): Barry Backiewicz, D.D.S.; Decision and Order, 2026-10-26 - [2026-21799](https://policyrisk.com/federal-register/2026-21799): Vida Janson, M.D.; Decision and Order, 2026-10-26 ## Sources - [2025-09988 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/03/2025-09988/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) - [2025-09988 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-03/pdf/2025-09988.pdf) ## Related - [Previous: 2025-09983, Designation of Propionyl Chloride as a List I Chemical](https://policyrisk.com/federal-register/2025-09983) - [Next: 2025-09991, Rescission of Affirmative Fair Housing Marketing Regulations](https://policyrisk.com/federal-register/2025-09991) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2025-09988 (as of 2026-10-27).